Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

Securities reiterated an Outperform rating on Verastem stock (NASDAQ:VSTM), with a steady price target of $9.00. The firm's ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

Barclays PLC raised its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...

Boston, USA-based Verastem Oncology today announced the appointment of Matthew Ros as chief operating officer (COO). In his role, Mr Ros will report to Dan Paterson, president and chief executive, and ...